In vivo experiments were conducted on male C57BL/6J mice (820 weeks old), divided into cohorts corresponding to two separate dosages (1 g/10 mL/kg or 3 g/10 mL/kg) of individual sugar solutions or an equivalent saline solution (control)
For people with MS who also have obesity or type 2 diabetes, GLP-1 medications may be worth discussing with a neurologist and primary care provider, though their long-term impact on MS is still unknown
If you experience persistent side effects at any dose, your provider may extend the time at that level before escalating
Some content may be partially generated by artificial intelligence tools, which can lead to inaccuracies
Just know you may need to plan around potential delays, especially for first shipments
Rescheduled procedurescosting you time, added stress, and possibly delaying a diagnosis